Transforming cancer treatment and advancing new therapies through empowered science

Corporate Profile

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

The company’s lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited is commercially available for two indications in 50 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage programs designed to address the unmet medical needs of people with cancer, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle Genetics’ ADC technology is employed by a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. Across both internal and collaborator programs, there are more than 20 ADCs in clinical development using our proprietary approach to empowering antibodies.

Download Documentation  Corporate Fact Sheet
Download Documentation  2013 Annual Report
Download Documentation  2014 Proxy Statement
Investor Contact
Peggy Pinkston
Executive Director, Corporate Communications
PHONE: (425) 527-4160
FAX: (425) 527-4001
EMAIL: ppinkston@seagen.com

Media Contact
Tricia Larson
Director, Public Relations
PHONE: 425-527-4180
EMAIL: tlarson@seagen.com
Stock Quote
SGEN (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$35.35
Change (%)0.00 (0.00%)
Volume0
Data as of 03/31/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >
DateTitle 
02/25/15Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 25, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Cowen and Company 35th Annual Health Care Conference Tuesday, March 3, 8:40 a.m. Eastern Tim... 
Printer Friendly Version
02/18/15Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 18, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 AETHERA trial of ADCETRIS (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma (HL) patients at high risk of relapse. A... 
Printer Friendly Version
02/17/15Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors
-SEA-CD40 Utilizes Sugar-Engineered Antibody Technology Designed to Target CD40 and Stimulate the Immune System- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 17, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1 clinical trial of SEA-CD40 for multiple types of advanced solid tumors. SEA-CD40 is a novel investigational immuno-oncology agent targeted to CD40, a widely expressed stimulatory receptor found on ant... 
Printer Friendly Version
02/10/15Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results
-Total 2014 Revenues of $286.8 Million, Including $178.2 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Phase 3 AETHERA Supplemental BLA Submission Planned in First Quarter 2015- -Conference Call Today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 10, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December... 
Printer Friendly Version
02/05/15Seattle Genetics to Present at Leerink Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 5, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the Leerink Global Healthcare Conference on Thursday, February 12, at 11:35 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.